This Is MS Multiple Sclerosis Knowledge & Support Community

Roche Holding AG Friday said mid-stage trials of a experimental multiple sclerosis medicine ocrelizumab showed the drug to significantly reduce disease activity in patients with relapsing-remitting multiple sclerosis, raising hopes the medicine could make it to the market and eventually turn into a blockbuster.

Developed by U.S.-based Biogen Idec Inc (BIIB) and Roche unit Genentech, ocrelizumab was recently abandoned in treating patients suffering from rheumatoid arthritis due to an unfavourable risk profile, raising concerns the drug could be discarded in other indications, a step that would have weakened Roche’s pipeline...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397

They are definitely moving this one along. I moved ocrelizumab to phase 3 on the pipeline list as they are starting a phase 3 trial for primary progressive MS.

http://www.clinicaltrials.gov/ct2/show/NCT01194570